NewsBenzingaRapport Therapeutics Announces That Topline Results From Its Phase 2 Trial Of RAP-219 In Adults With Acute Bipolar Mania Met Primary Endpoint Rapport Therapeutics Announces That Topline Results From Its Phase 2 Trial Of RAP-219 In Adults With Acute Bipolar Mania Met Primary Endpoint Benzinga 2026.10.20 10:09 (GMT+0) Open on Benzinga Other news Cantor Fitzgerald Maintains Overweight on VinFast Auto, Lowers Price Target to $4 'Projects Signal AI Copper Use May Triple by 2028, Trafigura Says' - Bloomberg Cantor Fitzgerald Reiterates Overweight on Tesla, Maintains $485 Price Target Nebius Group Stock Is Falling Tuesday: What's Going On? B of A Securities Maintains Buy on Gilead Sciences, Raises Price Target to $172 'Codelco Sets European Copper Premium at Record $350 a Ton'- Bloomberg
